Scarica l'app Stockscreener
4.41
2.22%
-0.10
Dopo l'orario di chiusura:
4.42
0.010
+0.23%
Precedente Chiudi:
$4.51
Aprire:
$4.46
Volume 24 ore:
2.41M
Relative Volume:
0.46
Capitalizzazione di mercato:
$1.53B
Reddito:
$62.90M
Utile/perdita netta:
$-204.63M
Rapporto P/E:
-7.3537
EPS:
-0.5997
Flusso di cassa netto:
$-181.78M
1 W Prestazione:
-0.23%
1M Prestazione:
-24.49%
6M Prestazione:
+18.87%
1 anno Prestazione:
+146.37%
Intervallo 1D:
$4.41
$4.605
Intervallo di 1 settimana:
$4.045
$4.605
Portata 52W:
$1.54
$9.75
Nuvation Bio Inc Stock (NUVB) Company Profile
Nome
Nuvation Bio Inc
Settore
Industria
Telefono
332-208-6102
Indirizzo
1500 BROADWAY, NEW YORK
Compare NUVB vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
4.41 | 1.53B | 62.90M | -204.63M | -181.78M | -0.5997 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-11-19 | Iniziato | B. Riley Securities | Buy |
| 2025-09-30 | Iniziato | Jefferies | Buy |
| 2025-04-23 | Iniziato | Citizens JMP | Mkt Outperform |
| 2024-03-27 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-03-26 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2023-01-06 | Downgrade | Jefferies | Buy → Hold |
| 2022-08-02 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-08-02 | Downgrade | BTIG Research | Buy → Neutral |
| 2022-05-04 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2021-04-06 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-03-08 | Iniziato | BMO Capital Markets | Outperform |
| 2021-03-08 | Iniziato | BTIG Research | Buy |
| 2021-03-08 | Iniziato | Cowen | Outperform |
| 2021-03-08 | Iniziato | Jefferies | Buy |
| 2021-03-08 | Iniziato | Wedbush | Outperform |
Mostra tutto
Nuvation Bio Inc Borsa (NUVB) Ultime notizie
Aug Reactions: Is Nuvation Bio Inc exposed to currency risks2026 Price Momentum & Daily Profit Focused Stock Screening - baoquankhu1.vn
Is EMA Validation Of Taletrectinib Expanding Nuvation Bio’s (NUVB) Targeted Lung Cancer Opportunity? - Sahm
Bullish analyst sentiment on Nuvation Bio (NUVB) amid early commercialization progress - MSN
2026-04-03 | Bronstein, Gewirtz & Grossman, LLC Encourages Nuvation Bio Inc. (NUVB) Shareholders to Inquire about Securities Investigation | NYSE:NUVB | Press Release - Stockhouse
Nuvation Bio Inc. (NUVB) amends protocol on safusidenib trials in astrocytoma - MSN
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact L - GuruFocus
Nuvation Bio Inc. (NUVB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Nuvation Bio gains global rights to brain cancer therapy from Daiichi Sankyo - MSN
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nuvation Bio Inc. (NUVB) And Encourages Investors to Connect - ACCESS Newswire
Nuvation Bio (NYSE:NUVB) Earns "Outperform" Rating from Wedbush - MarketBeat
NUVB Stock Price, Quote & Chart | NUVATION BIO INC (NYSE:NUVB) - ChartMill
Nuvation Bio secures global rights to safusidenib from Daiichi Sankyo By Investing.com - Investing.com Australia
Truist reiterates Buy on Nuvation Bio stock, $12 target on Japan deal - Investing.com Australia
Nuvation Bio announces acquisition of Japan rights to safusidenib from Daiichi Sankyo - MarketScreener
Nuvation Bio Announces Acquisition Of Japan Rights To Safusidenib From Daiichi Sankyo - TradingView
Nuvation gains global rights to brain cancer drug (NUVB:NYSE) - Seeking Alpha
Nuvation Bio secures global rights to safusidenib from Daiichi Sankyo - Investing.com
Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo - PR Newswire
Nuvation Bio Inc. (NUVB) and Eisai Get EMA Validation for Taletrectinib - Insider Monkey
Nuvation Bio Inc. (NUVB): Billionaire David Abrams has a long-term bet on this stock - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Nuvation Bio Inc. (NUVB) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
5 Best Stocks Under $10 to Buy and Hold Forever - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nuvation Bio Inc. (NUVB) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
A Look At Nuvation Bio’s Valuation As EMA Validates Taletrectinib Application In Europe - Sahm
Nuvation Bio, Eisai application for taletrectinib for NSCLC accepted by EMA - MSN
Eisai And Nuvation Bio Advance Taletrectinib With EMA Validation For ROS1 Positive Lung Cancer - BioPharma APAC
Profit Review: Can Nuvation Bio Inc sustain earnings growth2026 Institutional & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Nuvation Bio outlines first-line IBTROZI growth strategy with 50-month median DOR amid expanding global partnerships - MSN
H.C. Wainwright reiterates Nuvation Bio stock rating on EU filing By Investing.com - Investing.com India
Nuvation Bio Inc. (NUVB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - accessnewswire.com
Wedbush Reiterates Outperform Rating for Nuvation Bio (NYSE:NUVB) - MarketBeat
H.C. Wainwright reiterates Nuvation Bio stock rating on EU filing - Investing.com
H.C. Wainwright Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $17 - Moomoo
March 2026's Promising Penny Stocks To Watch - simplywall.st
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency - JCN Newswire
Nuvation Bio Inc. (NUVB): Billionaire David Abrams Has a Long-Term Bet on This Stock - Yahoo Finance
12 Best Stocks to Buy According to Billionaire David Abrams - Insider Monkey
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc.NUVB - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Nuvation Bio Inc. (NUVB) Investors to Inquire about Securities Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio ... - caledonianrecord.com
2026-03-24 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nuvation Bio Inc. (NUVB) And Encourages Investors to Reach Out | NYSE:NUVB | Press Release - Stockhouse
Nuvation Bio (NUVB)’s Taletrectinib Selected as Preferred Agent for Cancer Treatment - MSN
NUVB Investors Have Opportunity to Join Nuvation Bio Inc. Fraud Investigation with the Schall Law Firm - weeklyvoice.com
Is It Time To Reassess Nuvation Bio (NUVB) After Its Recent Share Price Swings - Yahoo Finance
Nuvation Bio Inc Azioni (NUVB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):